Compassionate Use of Ibalizumab for the Treatment of HIV Infection

NCT02028819 NO_LONGER_AVAILABLE

Ibalizumab is a humanized immunoglobulin G monoclonal antibody directed against a human T-cell receptor (CD4) and thus suppresses HIV replication by blocking entry of HIV into CD4+ lymphocytes. Ibalizumab has completed phase I and II clinical studies in HIV-negative and HIV-infected individuals showing safety and efficacy for suppressing HIV replication.

Details

Lead sponsor	University of Colorado, Denver
Status	NO_LONGER_AVAILABLE
Start date	2012-01
Completion	2014-02

Conditions

• Human Immunodeficiency Virus (HIV)

Interventions

• Dolutegravir Sodium Monohydrate
• Ibalizumab

Countries

United States